Transposable Element Is Predictive of Chemotherapy- and Immunotherapy-Related Overall Survival in Glioma
Open Access
- 12 May 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1177
Abstract
Background: Glioma is the most common type of malignant brain tumor. Temozolomide (TMZ) is a limited systematic treatment option for glioma, including low-grade glioma (LGG) and glioblastoma (GBM). However, not all patients benefit from TMZ and some develop resistance to it. MGMT methylation has been used to identify patients who may benefit from TMZ, but it is not effective in all cases. Objectives: There is an urgent need for new biomarkers to predict the survival of patients who receive TMZ. Methods: We utilized a recently developed method called REdiscoverTE to precisely measure the expression of transposable elements (TE). We performed Cox regression analysis to assess the predictive ability for prognosis and conducted a series of correlation studies to uncover potential mechanisms. Results: We identified three TEs, LTR81B, LTR27B, and MER39B, that were strongly predictive of longer survival in glioma patients receiving chemotherapy. We discovered that the expression of these TEs was positively associated with immune cells that enhance the immune system and negatively associated with immune cells suppressing the immune response, as well as molecules that control immune checkpoints. These three TEs were also found to predict better survival in patients receiving immunotherapy. Conclusions: In conclusion, we demonstrate that the expression of TEs can serve as a novel biomarker for the overall survival of glioma patients who receive TMZ chemotherapy or immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82303830)
This publication has 38 references indexed in Scilit:
- Genome-wide identification and analysis of prognostic features in human cancersCell Reports, 2022
- SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening DatasetsGenomics, Proteomics & Bioinformatics, 2022
- Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancerEuropean Journal of Cancer, 2021
- Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- MGMT Status as a Clinical Biomarker in GlioblastomaTrends in Cancer, 2020
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- Surgical Management of Incidental GliomasNeurosurgery Clinics of North America, 2017
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009